|February 12, 2003|
Taisho Launches "Menfula Cool <IM>" Poultice With 0.5% Indomethacin, Same Concentration as in Prescription Drugs
|Taisho Pharmaceutical Co., Ltd. (President: Akira Uehara) announces the launch of "Menfula Cool <IM>", a poultice formulated with the anti-inflammatory and analgesic indomethacin, at a concentration of 0.5%, the same concentration as found in prescription drugs, in late March.
Poultices containing 0.375% indomethacin have been on the market for some time, but this will be the first OTC product to contain 0.5%, the same concentration as in prescription drugs.
"Menfula Cool <IM>" inhibits the pain producing and intensifying substance prostaglandins, relieving muscle aches and pains, joint pain, stiff shoulders, backache, bruising, sprains, etc. The poultice is highly stretchable in its length and width and on a bias, and will stay put even during vigorous movement. Menfula Cool <IM> features a cooling sensation and an inoffensive scent when applied.
Taisho Pharmaceutical launched the "Menfula" brand of analgesic and anti-inflammatory products for external use 66 years ago, in 1936. Since then, Taisho has continued to expand the lineup to meet diversifying user demands, through the development of new product formats and the modification of initial prescriptions. The addition of "Menfula Cool <IM>" will further strengthen the "Menfula" series.